The bio-tech company Leidos Holdings Inc. is making significant waves in the market. Its impressive performance exceeded market expectations, with the first-quarter financial results for 2025 beating estimates. Investors are responding positively, as seen in strong stock activity with a decent 56% return over the last three years and a 55% gain for investors five years ago. Key institutions such as Marshall Wace LLP, AXA S.A., Alyeska Investment Group, and others are strengthening their Leidos Holdings positions, reflecting confidence in the firm's value.
Additionally, Leidos Q1 Earnings report revealed a profitable increase, highlighted by a $0.50 boost in earnings per share and revenues surpassing expectations. Northern Trust Corp's stake in the company is worth a substantial $174.03 million. The company finalized key amendments and approved significant stock sales. Leidos Holdings has also secured a massive $205M Pentagon Contract for AI and Zero Trust Security deployment at DTRA.
Furthermore, target prices for Leidos have been increased by notable financial institutions, including Wells Fargo, RBC Capital, and UBS analyst and Truist. Its quarterly dividend distribution is set at $0.40, expected to be paid on June 30.
Leidos Holdings LDOS News Analytics from Fri, 14 Feb 2025 08:00:00 GMT to Sun, 11 May 2025 00:59:04 GMT - Rating 8 - Innovation 5 - Information 7 - Rumor -2
